company background image
NTLA

Intellia Therapeutics NasdaqGM:NTLA Stock Report

Last Price

US$55.96

Market Cap

US$4.3b

7D

3.8%

1Y

-58.3%

Updated

30 Sep, 2022

Data

Company Financials +
NTLA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NTLA Stock Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.

Intellia Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share PriceUS$55.96
52 Week HighUS$143.92
52 Week LowUS$37.08
Beta2.02
1 Month Change-6.83%
3 Month Change3.61%
1 Year Change-58.26%
3 Year Change360.96%
5 Year Change80.93%
Change since IPO153.21%

Recent News & Updates

Sep 01

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Intellia Therapeutics (NASDAQ:NTLA) on Thursday said the U.S. FDA had granted an orphan drug designation to the company's genome editing candidate NTLA-2002 for the treatment of hereditary angioedema (HAE), a disorder characterized by recurring episodes of severe swelling. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. Intellia (NTLA) said its NTLA-2002 investigational therapy is designed to target the KLKB1 gene to reduce plasma kallikrein activity and thus prevent HAE attacks. The therapy is currently being evaluated in an early-to-mid stage trial in adults with type I or II HAE. The company expects to present interim data on NTLA-2002 at a symposium later this month. NTLA stock earlier closed -0.2% at $59.97.

Shareholder Returns

NTLAUS BiotechsUS Market
7D3.8%0.4%-2.5%
1Y-58.3%-25.6%-23.2%

Return vs Industry: NTLA underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: NTLA underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is NTLA's price volatile compared to industry and market?
NTLA volatility
NTLA Average Weekly Movement11.6%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: NTLA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NTLA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014485John Leonardhttps://www.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.

Intellia Therapeutics Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
NTLA fundamental statistics
Market CapUS$4.25b
Earnings (TTM)-US$400.43m
Revenue (TTM)US$45.34m

93.8x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTLA income statement (TTM)
RevenueUS$45.34m
Cost of RevenueUS$344.94m
Gross Profit-US$299.60m
Other ExpensesUS$100.83m
Earnings-US$400.43m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.27
Gross Margin-660.79%
Net Profit Margin-883.17%
Debt/Equity Ratio0%

How did NTLA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NTLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTLA?

Other financial metrics that can be useful for relative valuation.

NTLA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue75.3x
Enterprise Value/EBITDA-9x
PEG Ration/a

Price to Book Ratio vs Peers

How does NTLA's PB Ratio compare to its peers?

NTLA PB Ratio vs Peers
The above table shows the PB ratio for NTLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average9.7x
CERE Cerevel Therapeutics Holdings
9.7x-7.3%US$4.4b
CCXI ChemoCentryx
15.7x73.1%US$3.7b
ALKS Alkermes
3.4x77.2%US$3.7b
IONS Ionis Pharmaceuticals
10x40.0%US$6.3b
NTLA Intellia Therapeutics
4.8x-1.7%US$4.3b

Price-To-Book vs Peers: NTLA is good value based on its Price-To-Book Ratio (4.8x) compared to the peer average (9.7x).


Price to Earnings Ratio vs Industry

How does NTLA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: NTLA is expensive based on its Price-To-Book Ratio (4.8x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is NTLA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTLA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NTLA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of NTLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-1.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NTLA's revenue (63.1% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: NTLA's revenue (63.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NTLA is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Intellia Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-38.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NTLA is currently unprofitable.

Growing Profit Margin: NTLA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.

Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: NTLA has a negative Return on Equity (-45.48%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Intellia Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NTLA's short term assets ($895.4M) exceed its short term liabilities ($123.8M).

Long Term Liabilities: NTLA's short term assets ($895.4M) exceed its long term liabilities ($106.1M).


Debt to Equity History and Analysis

Debt Level: NTLA is debt free.

Reducing Debt: NTLA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTLA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NTLA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 41.3% each year.


Discover healthy companies

Dividend

What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Intellia Therapeutics Dividend Yield vs Market
How does Intellia Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Intellia Therapeutics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Intellia Therapeutics)0%

Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTLA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

John Leonard (65 yo)

8.17yrs

Tenure

US$9,773,560

Compensation

Dr. John M. Leonard, M.D., is an Executive Partner at Tyree & D'Angelo Partners. He has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Le...


CEO Compensation Analysis

John Leonard's Compensation vs Intellia Therapeutics Earnings
How has John Leonard's remuneration changed compared to Intellia Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$400m

Mar 31 2022n/an/a

-US$369m

Dec 31 2021US$10mUS$600k

-US$268m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$185m

Mar 31 2021n/an/a

-US$149m

Dec 31 2020US$4mUS$580k

-US$134m

Sep 30 2020n/an/a

-US$120m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$109m

Dec 31 2019US$904kUS$559k

-US$100m

Sep 30 2019n/an/a

-US$90m

Jun 30 2019n/an/a

-US$89m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018US$10mUS$550k

-US$85m

Sep 30 2018n/an/a

-US$90m

Jun 30 2018n/an/a

-US$83m

Mar 31 2018n/an/a

-US$76m

Dec 31 2017US$3mUS$396k

-US$68m

Sep 30 2017n/an/a

-US$54m

Jun 30 2017n/an/a

-US$46m

Mar 31 2017n/an/a

-US$38m

Dec 31 2016US$2mUS$300k

-US$32m

Sep 30 2016n/an/a

-US$26m

Jun 30 2016n/an/a

-US$22m

Mar 31 2016n/an/a

-US$18m

Dec 31 2015US$450kUS$300k

-US$12m

Compensation vs Market: John's total compensation ($USD9.77M) is above average for companies of similar size in the US market ($USD6.85M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NTLA's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: NTLA's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of NTLA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,277,9131.7%
General Public3,109,5754.1%
Public Companies5,879,1437.7%
Institutions65,745,15386.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.4%.


Top Shareholders

Top 25 shareholders own 73.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.52%
ARK Investment Management LLC
9,514,580$532.4m5.94%3.63%
8.56%
The Vanguard Group, Inc.
6,509,282$364.3m1.84%0.01%
7.75%
BlackRock, Inc.
5,887,399$329.5m5.1%0.01%
4.87%
Regeneron Pharmaceuticals, Inc.
3,702,995$207.2m0%no data
4.35%
FMR LLC
3,304,943$184.9m18.27%0.02%
4.14%
State Street Global Advisors, Inc.
3,143,811$175.9m31.13%0.01%
3.66%
Nikko Asset Management Co., Ltd.
2,781,136$155.6m-3.17%0.07%
2.93%
Viking Global Investors LP
2,228,383$124.7m-9.74%0.59%
2.86%
Novartis AG
2,176,148$121.8m0%no data
2.69%
T. Rowe Price Group, Inc.
2,047,331$114.6m-7.77%0.01%
2.24%
AllianceBernstein L.P.
1,704,651$95.4m-2.46%0.04%
1.87%
Federated Hermes, Inc.
1,418,300$79.4m128.91%0.25%
1.7%
Geode Capital Management, LLC
1,292,588$72.3m5.36%0.01%
1.6%
Himension Capital (Singapore) Pte Ltd
1,216,340$68.1m63.45%8.02%
1.48%
Avidity Partners Management, L.P.
1,125,194$63.0m188.46%1.5%
1.36%
Chevy Chase Trust Company
1,036,305$58.0m-1.94%0.25%
1.21%
Dimensional Fund Advisors LP
918,898$51.4m-2.84%0.01%
1.03%
John Leonard
783,075$43.8m0%no data
1.03%
Morgan Stanley Investment Management Inc.
779,691$43.6m-1.24%0.03%
0.94%
Two Sigma Advisers, LP
715,217$40.0m63.29%0.12%
0.94%
Charles Schwab Investment Management, Inc.
713,445$39.9m2.45%0.01%
0.93%
Northern Trust Global Investments
704,057$39.4m2.09%0.01%
0.87%
Wellington Management Group LLP
659,899$36.9m-15.24%0.01%
0.84%
Pictet Asset Management Limited
635,850$35.6m73.48%0.03%
0.77%
Discovery Value Fund
584,483$32.7m-40.73%7.74%

Company Information

Intellia Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intellia Therapeutics, Inc.
  • Ticker: NTLA
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$4.254b
  • Shares outstanding: 76.01m
  • Website: https://www.intelliatx.com

Number of Employees


Location

  • Intellia Therapeutics, Inc.
  • 40 Erie Street
  • Suite 130
  • Cambridge
  • Massachusetts
  • 2139
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTLANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2016
38IDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2016
0JBULSE (London Stock Exchange)YesCommon StockGBUSDMay 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.